HIF1A and peripheral arterial disease: Interestingly, forced overexpression of HIF-1α has been tested in clinical gene therapy trials for peripheral artery disease and myocardial ischemia, with varying degrees of success, suggesting that temporal control and tissue targeting are critical factors for therapeutic benefit [126].